Bortezomib

What it is used for

Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma treatment of adult patients with mantle cell lymphoma 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

Side effects, and when to stop

The following clinically significant adverse reactions are also discussed in other sections of the labeling:

• Peripheral Neuropathy [ see Warnings and Precautions ]
• Hypotension [ see Warnings and Precautions ]
• Cardiac Toxicity [ see Warnings and Precautions ]
• Pulmonary Toxicity [ see Warnings and Precautions ]
• Posterior Reversible Encephalopathy Syndrome (PRES) [ see Warnings and Precautions ]
• Gastrointestinal Toxicity [ see Warnings and Precautions ]
• Thrombocytopenia/Neutropenia [ see Warnings and Precautions ]
• Tumor Lysis Syndrome [ see Warnings and Precautions ]
• Hepatic Toxicity [ see Warnings and Precautions ]
• Thrombotic Microangiopathy [ see Warnings and Precautions ( 5.10 ) ]

Who should not take it

Bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [ see Adverse Reactions ].

Bortezomib for injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib for injection.

Storing it

Unopened vials may be stored at controlled room temperature stored at 20°C to 25°C (68°F to 77°F) [USP Controlled room temperature]. Retain in original package to protect from light.

Follow guidelines for handling and disposal for hazardous drugs, including the use of gloves and other protective clothing to prevent skin contact 1